Sarepta would need to conduct new analyses to validate the safety of Elevidys—which has had U.S. shipments paused by the ...

Del-zota was granted FDA breakthrough therapy designation for treating DMD, and its developer is on track to seek its ...

As gene therapy maker Sarepta Therapeutics tangles with FDA over its Duchenne treatment, patients and their families are ...

This week on "The Readout LOUD" podcast, a mother whose son has Duchenne muscular dystrophy shares her perspective on Sarepta ...

Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...

Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those willing to dig deeper.

Key Points Sarepta Therapeutics' most crucial product is turning out to have severe safety issues. The company's efforts to improve its situation were well received, but this victory didn't last long.

A 15-year-old boy in New Market with a neuromuscular disorder received a wheelchair accessible van last week through the ...

A boy who was carried home from a birthday party suffering with what his parents thought was cramp has since been diagnosed with a rare muscle-wasting condition. Evan Winter, 7, from Langley, near ...

For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...

Roche has halted some international shipments of the gene therapy Elevidys, used to treat Duchenne muscular dystrophy, Bloomberg reported July 22. The decision comes in the wake of a similar move by ...